Ozempic may help people with serious mental health condition

Key Points:

• New research from Griffith University found that semaglutide, a GLP-1 drug sold as Ozempic and Wegovy, is associated with a 21% lower risk of psychiatric hospitalization in people with bipolar disorder, suggesting it may help stabilize extreme mood symptoms.
• GLP-1 receptor agonists like semaglutide may protect the brain by reducing inflammation and cellular stress, potentially improving mood stability in bipolar disorder beyond their known effects on diabetes and obesity.
• Other GLP-1 drugs such as liraglutide and dulaglutide did not show the same psychiatric benefits, indicating semaglutide’s unique potential in mental health treatment.
• Previous studies have shown GLP-1 medications may have antidepressant effects and reduce suicidal ideation, with anecdotal reports also suggesting improvements in ADHD symptoms like focus and impulsivity.
• While promising, further research is needed to confirm whether GLP-1 drugs directly improve symptoms of bipolar disorder and other mental health conditions.